A Pilot Trial of Rituxan in Refractory Myasthenia Gravis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions
Refractory Myasthenia Gravis
Interventions
DRUG

Rituximab (Rituxan)

Four weekly IV infusions of Rituxan with dosage individually calculated per subject.

Trial Locations (2)

13210

State University of New York, Syracuse

05405

University of Vermont Department of Neurology, Burlington

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Vermont

OTHER